Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [11 C]T-773 in nonhuman primates

Synapse
Akihiro TakanoChrister Halldin

Abstract

Because phosphodiesterase 10A (PDE10A) degrades both cyclic adenosine monophosphate and cyclic guanosine monophosphate and is distributed mainly in the striatum, PDE10A inhibitors have been considered to potentially be useful therapeutic agents for psychiatric and neurodegenerative diseases such as schizophrenia and Huntington's disease. We measured striatal PDE10A occupancy by TAK-063, a newly developed compound with high affinity and selectivity for PDE10A, using PET with [(11)C]T-773 in nonhuman primates. Two 123-min dynamic PET measurements were performed on three female rhesus monkeys, once at baseline and again after intravenous administration of different doses of TAK-063 (0.2-1.6 mg/kg). Total distribution volume (V(T)) was calculated with a two-tissue compartment model using metabolite-corrected plasma input. Although the in vitro autoradiography did not show high specific binding to [(11)C]T-773 in the cerebellum, V(T) in the cerebellum decreased after TAK-063 treatment. The specific binding to PDE10A (V(S)) was calculated as the difference of the V(T) between the target regions and the cerebellum. PDE10A occupancy was calculated as the percent change of V(S). The average PDE10A occupancy of the caudate nucleus and pu...Continue Reading

References

Dec 1, 1994·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H HallL Farde
Dec 24, 1998·Nuclear Medicine and Biology·H HallG Sedvall
Jul 19, 2000·Current Biology : CB·A M Graybiel
Oct 9, 2002·Current Drug Metabolism·Meihua Rose Feng
Sep 12, 2003·Brain Research·Thomas F SeegerFrank S Menniti
May 26, 2006·Expert Opinion on Pharmacotherapy·Michael KrebsMartin Schaefer
Jul 26, 2006·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Timothy M CoskranDiane T Stephenson
May 14, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Andrea VarroneLars Farde
Aug 8, 2009·The Journal of Pharmacology and Experimental Therapeutics·Steven M GrauerNicholas J Brandon
Sep 10, 2009·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Vincent J CunninghamRoger N Gunn
Jun 29, 2010·Trends in Pharmacological Sciences·Caline S KaramJonathan A Javitch
Mar 2, 2011·Current Pharmaceutical Design·Jan Kehler, Jacob Nielsen
Jul 12, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Koen Van LaereMichel Koole
Dec 3, 2014·Nuclear Medicine and Biology·Akina HaradaHaruhide Kimura
Dec 20, 2014·The Journal of Pharmacology and Experimental Therapeutics·Kazunori SuzukiHaruhide Kimura
Jan 28, 2015·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Miklós TóthChrister Halldin
Apr 22, 2015·Journal of Labelled Compounds & Radiopharmaceuticals·Vladimir StepanovChrister Halldin
Jul 23, 2015·Brain : a Journal of Neurology·Flavia NiccoliniMarios Politis
Jul 27, 2015·Brain : a Journal of Neurology·Flavia NiccoliniMarios Politis

❮ Previous
Next ❯

Citations

May 24, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Susann SchröderPeter Brust
Apr 7, 2017·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Haruhide Kimura
Sep 22, 2019·European Journal of Nuclear Medicine and Molecular Imaging·Stuart P McCluskeyOliver Howes
Jul 1, 2020·The International Journal of Neuropsychopharmacology·Thomas A MacekHaruhide Kimura
May 28, 2021·Journal of Medicinal Chemistry·Jiyun SunSteven H Liang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.